Matsubara N - Search Results

1

Phase 1 study of darolutamide (ODM-201): a new-generation androgen receptor antagonist, in Japanese patients with metastatic castration-resistant prostate cancer.

Matsubara N, Mukai H, Hosono A, Onomura M, Sasaki M, Yajima Y, Hashizume K, Yasuda M, Uemura M, Zurth C. Matsubara N, et al. Cancer Chemother Pharmacol. 2017 Dec;80(6):1063-1072. doi: 10.1007/s00280-017-3417-3. Epub 2017 Aug 11. Cancer Chemother Pharmacol. 2017. PMID: 28801852 Free PMC article. Clinical Trial.

2

Review of primary unknown cancer: cases referred to the National Cancer Center Hospital East.

Matsubara N, Mukai H, Nagai S, Itoh K. Matsubara N, et al. Int J Clin Oncol. 2010 Dec;15(6):578-82. doi: 10.1007/s10147-010-0112-3. Epub 2010 Aug 11. Int J Clin Oncol. 2010. PMID: 20700615

3

Long-term outcome of pleurodesis with OK-432 in metastatic breast cancer: a new risk model for success from an analysis of 75 cases.

Matsubara N, Itoh K, Mukai H, Nagai S. Matsubara N, et al. Int J Clin Oncol. 2012 Oct;17(5):470-6. doi: 10.1007/s10147-011-0312-5. Epub 2011 Oct 7. Int J Clin Oncol. 2012. PMID: 21979749

4

Prognostic impact of Ki-67 overexpression in subgroups categorized according to St. Gallen with early stage breast cancer.

Matsubara N, Mukai H, Itoh K, Nagai S. Matsubara N, et al. Oncology. 2011;81(5-6):345-52. doi: 10.1159/000334920. Epub 2012 Jan 13. Oncology. 2011. PMID: 22248824

5

Comparison between neoadjuvant and adjuvant gemcitabine plus cisplatin chemotherapy for muscle-invasive bladder cancer.

Matsubara N, Mukai H, Naito Y, Nezu M, Itoh K. Matsubara N, et al. Asia Pac J Clin Oncol. 2013 Dec;9(4):310-7. doi: 10.1111/ajco.12017. Epub 2012 Nov 6. Asia Pac J Clin Oncol. 2013. PMID: 23127231 Free PMC article.

6

Different prognostic significance of Ki-67 change between pre- and post-neoadjuvant chemotherapy in various subtypes of breast cancer.

Matsubara N, Mukai H, Fujii S, Wada N. Matsubara N, et al. Breast Cancer Res Treat. 2013 Jan;137(1):203-12. doi: 10.1007/s10549-012-2344-6. Epub 2012 Nov 27. Breast Cancer Res Treat. 2013. PMID: 23184081

7

First experience of active surveillance before systemic target therapy in patients with metastatic renal cell carcinoma.

Matsubara N, Mukai H, Naito Y, Itoh K, Komai Y, Sakai Y. Matsubara N, et al. Urology. 2013 Jul;82(1):118-23. doi: 10.1016/j.urology.2013.03.035. Urology. 2013. PMID: 23806397

8

Survival outcome and reduction rate of Ki-67 between pre- and post-neoadjuvant chemotherapy in breast cancer patients with non-pCR.

Matsubara N, Mukai H, Masumoto M, Sasaki M, Naito Y, Fujii S, Wada N. Matsubara N, et al. Breast Cancer Res Treat. 2014 Aug;147(1):95-102. doi: 10.1007/s10549-014-3084-6. Epub 2014 Aug 9. Breast Cancer Res Treat. 2014. PMID: 25106660

9

Phase 1 combination study of eribulin mesylate with trastuzumab for advanced or recurrent human epidermal growth factor receptor 2 positive breast cancer.

Mukai H, Saeki T, Shimada K, Naito Y, Matsubara N, Nakanishi T, Obaishi H, Namiki M, Sasaki Y. Mukai H, et al. Among authors: matsubara n. Invest New Drugs. 2015 Feb;33(1):119-27. doi: 10.1007/s10637-014-0161-y. Epub 2014 Sep 23. Invest New Drugs. 2015. PMID: 25242374 Free PMC article. Clinical Trial.

10

Overall survival and final efficacy and safety results from a Japanese phase II study of axitinib in cytokine-refractory metastatic renal cell carcinoma.

Eto M, Uemura H, Tomita Y, Kanayama H, Shinohara N, Kamei Y, Fujii Y, Umeyama Y, Ozono S, Naito S, Akaza H; Japan Axitinib Phase II Study Group. Eto M, et al. Cancer Sci. 2014 Dec;105(12):1576-83. doi: 10.1111/cas.12546. Epub 2014 Nov 25. Cancer Sci. 2014. PMID: 25283266 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

530 results

Search Page

Filters